Clinical Trial Update: Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability and pharmacokinetics of inhaled GSK2269557 via the ELLIPTA inhaler in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• GSK2269557

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 1 | Status: COMPLETED